Stockscreener 앱 받기
4.27
0.81%
-0.04
전일 마감가:
$4.31
열려 있는:
$4.28
하루 거래량:
1,760
Relative Volume:
0.03
시가총액:
$81.58M
수익:
-
순이익/손실:
$-34.17M
주가수익비율:
-1.8865
EPS:
-2.2635
순현금흐름:
$-47.63M
1주 성능:
+0.83%
1개월 성능:
+2.03%
6개월 성능:
+27.99%
1년 성능:
+72.38%
1일 변동 폭
$4.27
$4.29
1주일 범위
$4.04
$4.41
52주 변동 폭
$2.44
$5.12
폴리피드 Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.275 | 82.25M | 0 | -34.17M | -47.63M | -2.2635 |
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.04 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.53 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.40 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
폴리피드 Stock (PYPD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 개시 | Roth Capital | Buy |
| 2025-06-02 | 재개 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2021-09-14 | 개시 | JMP Securities | Mkt Outperform |
| 2021-07-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 개시 | Alliance Global Partners | Buy |
| 2020-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2020-07-21 | 개시 | Barclays | Overweight |
| 2020-07-21 | 개시 | Raymond James | Outperform |
모두보기
폴리피드 주식(PYPD)의 최신 뉴스
Short Covering: How much upside does PolyPid Ltd have2026 Key Lessons & Weekly High Return Stock Forecasts - baoquankhu1.vn
PYPD Options Volatility — NASDAQ:PYPD - TradingView — Track All Markets
PYPD Options Chain — NASDAQ:PYPD - TradingView — Track All Markets
Market Rankings: Is PolyPid Ltd likely to announce a buybackPortfolio Gains Summary & Smart Swing Trading Techniques - baoquankhu1.vn
PYPD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Gainers: Does PolyPid Ltd have high return on assets2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn
PolyPid Ltd. (NASDAQ:PYPD) Q4 2025 earnings call transcript - MSN
PolyPid (PYPD) director submits initial Form 3 ownership - Stock Titan
PolyPid (PYPD) director details vested and future stock options - Stock Titan
Total equity of PolyPid Ltd. – FWB:2PV - TradingView
Total debt of PolyPid Ltd. – FWB:2PV - TradingView
PolyPid Ltd. Balance Sheet – FWB:2PV - TradingView
Cash per share of PolyPid Ltd. – FWB:2PV - TradingView — Track All Markets
PolyPid Ltd. Stock (2PV)Quote Deutsche Boerse AG - marketscreener.com
PolyPid Ltd.: Target Price Consensus and Analysts Recommendations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Revenue and Earnings Analysts Forecasts Revisions | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Financial Data Forecasts Estimates and Expectations | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Shareholders Board Members Managers and Company Profile | IL0011326795 - marketscreener.com
PolyPid Ltd.: Fundamental Analysis and Financial Ratings | 2PV | IL0011326795 - marketscreener.com
PolyPid Ltd.: Performance & Quotes, 2PV Stock Price on Deutsche Boerse AG Exchange - marketscreener.com
Taxes of PolyPid Ltd. – FWB:2PV - TradingView
2PV: Static price chart | PolyPid Ltd. | IL0011326795 - marketscreener.com
Net income of PolyPid Ltd. – FWB:2PV - TradingView
2PV Stock Price and Chart — FWB:2PV - TradingView
PolyPid begins rolling NDA submission for surgical infection drug By Investing.com - Investing.com South Africa
PYPD Should I Buy - Intellectia AI
Polypid Ltd Initiates D-Plex100 Nda Submission to Fda - MarketScreener
PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD) - TipRanks
Risk Check: Does PolyPid Ltd stock benefit from AI growth2026 Performance Recap & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Polypid initiates D-Plex100 NDA submission to the FDA - marketscreener.com
PolyPid begins rolling NDA submission for surgical infection drug - Investing.com
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA - Bitget
PolyPid (PYPD) advances Fast Track NDA for D-PLEX100 after strong Phase 3 data - Stock Titan
Aug Closing: How does PolyPid Ltd score in quality rankingsFed Meeting & Low Risk Entry Point Tips - baoquankhu1.vn
Insider Buy: Does PolyPid Ltd have high return on assetsBear Alert & Short-Term Swing Trade Alerts - baoquankhu1.vn
Patterns Watch: How much upside does PolyPid Ltd haveMarket Volume Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
PolyPid Ltd Stock: Innovative Drug Delivery Solutions in a Competitive Biotech Landscape - AD HOC NEWS
PolyPid (PYPD) COO details stock option and share holdings - Stock Titan
PolyPid (PYPD) director Dror-Darwish Nir lists six vested option grants - Stock Titan
PolyPid (PYPD) CFO details extensive employee stock option awards - Stock Titan
PolyPid (PYPD) director Barenholz discloses shares and multiple option grants - Stock Titan
PolyPid (PYPD) director Joseph BenAmram reports initial stock option grants - Stock Titan
Pullback Watch: Whats the beta of PolyPid Ltd stock2026 Risk Factors & Verified Short-Term Trading Plans - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Axsome Therapeutics (AXSM) - The Globe and Mail
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
PolyPid (PYPD) director discloses stock options on 17,456 shares - Stock Titan
PolyPid (PYPD) director details shares and vested stock options - Stock Titan
PolyPid (PYPD) CEO details stock and option holdings in Form 3 - Stock Titan
PolyPid (PYPD) deputy CEO discloses extensive employee stock options - Stock Titan
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - TipRanks
PolyPid receives $4.3M FDA fee waiver for D-PLEX100 application By Investing.com - Investing.com India
폴리피드 (PYPD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.62%
0.89%
자본화:
|
볼륨(24시간):